Abingdon, United Kingdom

Eoin Christopher Power

This inventor holds 1 USPTO granted patent. Top assignee: Amgen Inc.. Active years: 2009.


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 60(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eoin Christopher Power: Innovator in Pharmaceutical Compounds

Introduction

Eoin Christopher Power is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various medical conditions.

Latest Patents

Eoin holds a patent for "Substituted heterocyclic compounds and methods of use." This invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. The patent outlines a method for treating a wide range of conditions, including inflammation, arthritis, autoimmune diseases, and various types of cancer. The therapeutic applications of his invention are extensive, targeting ailments such as rheumatoid arthritis, multiple sclerosis, and even type 1 diabetes.

Career Highlights

Eoin is currently employed at Amgen Inc., a leading biotechnology company. His work focuses on innovative solutions in the pharmaceutical industry, contributing to advancements that can improve patient outcomes. His expertise in developing therapeutic compounds has positioned him as a valuable asset in his field.

Collaborations

Eoin collaborates with talented professionals, including Patricia Amouzegh and Chiara Ghiron. These partnerships enhance the research and development efforts at Amgen Inc., fostering an environment of innovation and creativity.

Conclusion

Eoin Christopher Power is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact numerous medical conditions. His contributions to the field exemplify the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…